RecruitingPhase 2Phase 3NCT06456528

QL0911 for the Treatment of Cancer Treatment-Induced Thrombocytopenia

Phase 2/3 Randomized, Double-blind, Placebo-controlled Study of QL0911 for the Treatment of Cancer Treatment-Induced Thrombocytopenia.

Sponsor

Qilu Pharmaceutical Co., Ltd.

Enrollment

235 participants

Start Date

Oct 22, 2024

Study Type

INTERVENTIONAL

Conditions

Cancer Treatment-induced Thrombocytopenia

Summary

To evaluate the efficacy and safety of QL0911 in cancer treatment-induced thrombocytopenia. Thrombocytopenia is a low number of platelets in the blood. Sometimes, thrombocytopenia is a side effect of cancer treatment.

Eligibility

Min Age: 18 YearsMax Age: 75 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Placebo, a drug called QL0911, and others for people with cancer treatment-induced thrombocytopenia. The study is currently recruiting participants at 2 locations. People eligible for this study include aged 18 Years to 75 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGQL0911

QL0911

DRUGQL0911 plus Placebo

QL0911 plus Placebo

DRUGPlacebo

Placebo

Locations(2)

Harbin First Hospital

Harbin, China

Nanjing Tianyinshan Hospital

Nanjing, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06456528

Related Trials

Safety and Efficacy of Umbilical Cord Blood Therapy for Cancer Therapy-Induced Thrombocytopenia (CTIT)

NCT074417201 location